Article

FACS‐purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia

Journal of Cellular and Molecular Medicine (Impact Factor: 4.01). 12/2011; 16(1):107 - 117. DOI: 10.1111/j.1582-4934.2011.01308.x

ABSTRACT

We recently developed a method to control the in vivo distribution of vascular endothelial growth factor (VEGF) by high throughput Fluorescence-Activated Cell Sorting (FACS) purification of transduced progenitors such that they homogeneously express specific VEGF levels. Here we investigated the long-term safety of this method in chronic hind limb ischemia in nude rats. Primary myoblasts were transduced to co-express rat VEGF-A164 (rVEGF) and truncated ratCD8a, the latter serving as a FACS-quantifiable surface marker. Based on the CD8 fluorescence of a reference clonal population, which expressed the desired VEGF level, cells producing similar VEGF levels were sorted from the primary population, which contained cells with very heterogeneous VEGF levels. One week after ischemia induction, 12 × 106 cells were implanted in the thigh muscles. Unsorted myoblasts caused angioma-like structures, whereas purified cells only induced normal capillaries that were stable after 3 months. Vessel density was doubled in engrafted areas, but only approximately 0.1% of muscle volume showed cell engraftment, explaining why no increase in total blood flow was observed. In conclusion, the use of FACS-purified myoblasts granted the cell-by-cell control of VEGF expression levels, which ensured long-term safety in a model of chronic ischemia. Based on these results, the total number of implanted cells required to achieve efficacy will need to be determined before a clinical application.

Download full-text

Full-text

Available from: Andrea Banfi
  • Source
    • "Using gene delivery systems such as retrovirally transduced myoblasts (Carmeliet, 2000; Lee et al., 2000), adeno-and adeno-associated viral vectors (Pettersson et al., 2000; Sundberg et al., 2001; Karvinen et al., 2011), and plasmid DNA (Isner et al., 1996; Schwarz et al., 2000), it was shown that uncontrolled VEGF expression induces the growth of vascular tumors (hemangiomas) in skeletal muscle (Springer et al., 1998), myocardium, and other tissues. However, we found evidence that VEGF does not have an intrinsically steep dose–response curve in vivo, but rather that the dose delivered must be controlled at the microenvironmental level (Ozawa et al., 2004; Von Degenfeld et al., 2006; Misteli et al., 2010; Melly et al., 2012; Wolff et al., 2012; Mujagic et al., 2013). In fact, due to the ECM-binding of VEGF, different GF concentrations remain tightly localized after secretion and a few " hotspots " of high expression can cause angioma growth even if the total dose is rather low. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood vessel growth plays a key role in regenerative medicine, both to restore blood supply to ischemic tissues and to ensure rapid vascularization of clinical-size tissue-engineered grafts. For example, vascular endothelial growth factor (VEGF) is the master regulator of physiological blood vessel growth and is one of the main molecular targets of therapeutic angiogenesis approaches. However, angiogenesis is a complex process and there is a need to develop rational therapeutic strategies based on a firm understanding of basic vascular biology principles, as evidenced by the disappointing results of initial clinical trials of angiogenic factor delivery. In particular, the spatial localization of angiogenic signals in the extracellular matrix (ECM) is crucial to ensure the proper assembly and maturation of new vascular structures. Here, we discuss the therapeutic implications of matrix interactions of angiogenic factors, with a special emphasis onVEGF, as well as provide an overview of current approaches, based on protein and biomaterial engineering that mimic the regulatory functions of ECM to optimize the signaling microenvironment of vascular growth factors.
    Full-text · Article · Apr 2015 · Frontiers in Bioengineering and Biotechnology
  • Source
    • "All the antibodies were used at a dilution of 1:50, except CD105-FITC, which was used at 1:20. CD8a expression was assessed by staining with a FITC-conjugated anti-rat CD8a antibody (clone OX-8; BD Pharmingen , San José, CA, USA), using previously optimized staining conditions [22] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rapid vascularisation of tissue-engineered osteogenic grafts is a major obstacle in the development of regenerative medicine approaches for bone repair. Vascular endothelial growth factor (VEGF) is the master regulator of vascular growth. We investigated a cell-based gene therapy approach to generate osteogenic grafts with an increased vascularization potential in an ectopic nude rat model in vivo, by genetically modifying human bone marrow-derived stromal/stem cells (BMSC) to express rat VEGF. BMSC were loaded onto silicate-substituted apatite granules, which are a clinically established osteo-conductive material. Eight weeks after implantation, the vascular density of constructs seeded with VEGF-BMSC was 3-fold greater than with control cells, consisting of physiologically structured vascular networks with both conductance vessels and capillaries. However, VEGF specifically caused a global reduction in bone quantity, which consisted of thin trabeculae of immature matrix. VEGF did not impair BMSC engraftment in vivo, but strongly increased the recruitment of TRAP- and Cathepsin K-positive osteoclasts. These data suggest that VEGF over-expression is effective to improve the vascularization of osteogenic grafts, but also has the potential to disrupt bone homoeostasis towards excessive degradation, posing a challenge to its clinical application in bone tissue engineering.
    Full-text · Article · Apr 2013 · Biomaterials
  • Source
    • "Our goal was to combine cell-based gene therapy and cardiac tissue engineering toward generating a fully viable cardiac patch with intrinsic vascularization potential. To this end, we took advantage of a FACS-based technique we recently developed to rapidly purify homogeneous populations of transduced cells producing a defined level of VEGF, to reliably induce robust and normal angiogenesis [27] [28]. This strategy is not directly applicable to cardiomyocytes, because they cannot be sufficiently expanded in vitro to allow efficient transduction and FACS-purification. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Key requirements for cardiac tissue engineering include the maintenance of cell viability and function and the establishment of a perfusable vascular network in millimeters thick and compact cardiac constructs upon implantation. We investigated if these requirements can be met by providing an intrinsic vascularization stimulus (via sustained action of VEGF secreted at a controlled rate by transduced myoblasts) to a cardiac patch engineered under conditions of effective oxygen supply (via medium flow through channeled elastomeric scaffolds seeded with neonatal cardiomyocytes). We demonstrate that this combined approach resulted in increased viability, vascularization and functionality of the cardiac patch. After implantation in a mouse model of myocardial infarction, VEGF-expressing patches displayed significantly improved engraftment, survival and differentiation of cardiomyocytes, leading to greatly enhanced contractility as compared to controls not expressing VEGF. Controlled VEGF expression also mediated the formation of mature vascular networks, both within the engineered patches and in the underlying ischemic myocardium. We propose that this combined cell-biomaterial approach can be a promising strategy to engineer cardiac patches with intrinsic and extrinsic vascularization potential.
    Full-text · Article · Jan 2013 · Biomaterials
Show more